tbuckley/cabot-search huggingface dataset:
Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment
Authors: F van Spronsen
Journal: Hepatology (1994)

Hereditary tyrosinemia type I (McKusick 27670) is a heterogeneous disease with poor prognosis, yet there are few reports of the long-term prognosis. It is therefore difficult to decide on the treatment for individual patients. We have conducted an international survey of patients with tyrosinemia type I and examined the probability of survival on dietary treatment and the causes of death in 108 patients with tyrosinemia type I. The survival after the onset of symptoms varied with the age at onset; the earlier the symptoms developed the poorer the outlook. Liver failure and recurrent bleeding (67%), hepatocellular carcinoma (17%) and the porphyria-like syndrome with respiratory failure (10%) were the most common causes of death. The 1-and 2-yr survival probability after the onset of symptoms in patients in whom symptoms developed before 2 mo, between 2 and 6 mo and after 6 mo were 38%/29%, 74%/74% and 96%/96%, respectively. On the basis of these survival rates, a new classification - which is important with respect to choices in treatment — is proposed: very early (onset of symptoms < 2 mo), early (2 to 6 mo) and late presenting form (>6 mo). (Hepatology 1994;20:1187–1191).
Highlights from this issue
Journal: Thorax (2018)

The TriumvirateThe 'Carry On' films consisted of 31 British comedies that were produced between 1958 and 1992.In this edition of Airwaves, we consider if 'Carry on Thorax' would have made the Director's cut… Carry on ColumbusAlthough it has been over 500 years since Christopher Columbus discovered the Americas in 1492, it took Kamdar et al from the US 5 years to investigate the occupational outcome of patients after acute respiratory distress syndrome (ARDS) (see page 125).In a 5-year multisite prospective longitudinal cohort study, 138 ARDS survivors were followed up with 31% never returning to work over 5 years of follow-up.Predictors of delayed return to work included baseline comorbidity, mechanical ventilation duration and discharge location.The loss of earnings ranged from £28,662 to £32,515 per person per year.
Notes on Pathology for Students' Use.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The neighborhood health center
Authors: F. L. Morton
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Bellin and Geiger (<b>214</b>:2147, 1970) have developed what would appear at initial glance to be an impressive case in proof of the acceptance and utilization of a Neighborhood Health Center (NHC) by urban poor. Evaluation efforts in this area are few,<sup>1</sup>difficult, and largely dependent on the primary interest of the investigator or sponsoring agency. While the "activity counts" dispel any doubt that the NHC was well utilized by the urban poor in 1965 to 1967, the study presents too many half-truths, poorly defined variables, and unproved assumptions about health attitudes and practices of the poor to be accepted without challenge. In the first place, the distinctions between the basic groups being studied are unclear. "Regular Source of Care," the distinguishing feature of the three categories, is not defined or particularized. It could easily mean one thing to one respondent and another to a second.
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.
Authors: George D. Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Heikki Joensuu, Robert G. Maki, Piotr Rutkowski, Peter Hohenberger, Hans Gelderblom, Michael Gordon Leahy, Margaret von Mehren, Patrick Schoffski, Martin E. Blackstein, Axel Le Cesne, Giuseppe Badalamenti, Jian-Ming Xu, Toshirou Nishida, Dirk Laurent, Iris Kuss, Paolo Giovanni Casali
Journal: Journal of Clinical Oncology (2012)

LBA10008 Background: Oral multikinase inhibitor regorafenib (REG) demonstrated substantial activity in a phase II trial in pts with GIST after failure of both IM and SU (J Clin Oncol. 2011; 29:606s; abstr 10007). This phase III, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of REG for this unmet clinical need. Methods: Eligible pts had metastatic and/or unresectable GIST, objective failure of both prior IM and SU (progressive disease [PD] on, or intolerance to, IM and PD on SU), ≥1 measurable lesion, ECOG performance status 0 or 1. Pts were randomized 2:1 to receive best supportive care plus either REG 160 mg po once daily (3 wks on/1 wk off) or placebo (PL). The primary endpoint was progression-free survival (PFS) (modified RECIST 1.1, independent central review). Secondary endpoints included overall survival (OS), disease control rate (DCR, defined as rate of partial response [PR] plus stable disease [SD] lasting for ≥12 wks), response rate and duration, safety and correlative genotype analyses. At time of PD, pts were eligible for unblinding and crossover to open-label REG. Results: Between Jan and Aug of 2011, 234 pts were screened; 199 were randomized (REG: 133, PL: 66). Pts were stratified at randomization according to number of prior systemic therapies and geographical region. Baseline characteristics were balanced between the two arms. The primary endpoint was met: median PFS was 4.8 months for REG vs. 0.9 months for PL. Hazard ratio for PFS was 0.27 (95% CI, 0.18-0.39), p&lt;0.0001. PFS rates at 3 and 6 months were 60% and 38% for REG vs. 11% and 0% for PL. DCR was 53% (REG) vs. 9% (PL).The HR for OS was 0.77 (p=0.20) with 85% PL pts having crossed over to REG. The most common &gt; grade 3 treatment-emergent AEs in the REG arm during double-blind study were hypertension (28%), hand-foot skin reaction (21%), and diarrhea (8%). Conclusions: This randomized trial demonstrated that REG significantly improved PFS and DCR in pts with advanced GIST after failure of at least prior IM and SU. REG was well tolerated, with AEs as expected for this class and manageable with dose modifications.
Combined childhood immunizations
Authors: P. R. Paradiso
Journal: JAMA (1992)

<h3>In Reply.</h3> —I have a friend whose father, an English teacher, once stopped his motorcycle in the middle of the Mojave Desert, unhitched the sidecar, and drove off, stranding a fellow teacher with whom he was arguing (heatedly, no doubt) a point of grammar. Dr Gitlitz, who admits "lack of reverence for [his] elders" and accuses me of "leading innocents astray," generates so much heat (and so little light) in his letter that I'm half afraid to try to set him straight. Take these two sentences: (1) Dr Gitlitz is not the only one who makes that mistake. (2) Dr Gitlitz is one of many who make that mistake. In each sentence, there is a main (independent or principal) clause and a subordinate (dependent, modifying, or qualifying) clause. In both sentences, the subject of the main clause is Dr Gitlitz and the subject of the subordinate clause is who. In
CALCIUM AND PHOSPHORUS IN THE BLOOD IN RICKETS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms
Authors: Ken Kamata, Masayuki Kitano, Masatoshi Kudo, Hiroki Sakamoto, Kumpei Kadosaka, Takeshi Miyata, Hajime Imai, Kiyoshi Maekawa, Takaaki Chikugo, Masashi Kumano, Tomoko Hyodo, Takamichi Murakami, Yasutaka Chiba, Yoshifumi Takeyama
Journal: Endoscopy (2014)

Correction to: Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasmsEndoscopy 2014; 46(01): 22-29DOI: 10.1055/s-0033-1353603
Who's Who in American Medicine 1925.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Patrick Roth, Jaap Reijneveld, Thierry Gorlia, Frederic Dhermain, Maureen Vanlancker, Beatrice Fournier, Sarah Nuyens, Chris O’Callaghan, Emilie Le Rhun, Ileana Elias, Martin van den Bent, Warren Mason, Benjamin Winograd, Michael Weller
Journal: Neuro-Oncology (2018)

The standard of care for patients with newly diagnosed glioblastoma includes maximum safe surgery, involved-field radiotherapy (RT), and concomitant and up to six cycles of maintenance temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). However, the prognosis remains poor and there is a high unmet need to provide new drugs to patients with glioblastoma. Marizomib is a novel, brain-penetrant irreversible pan-proteasome inhibitor that has been successfully assessed in phase I studies in patients with newly diagnosed as well as recurrent glioblastoma. EORTC 1709/CCTG CE.8 is a multicenter, randomized, controlled, open label phase III superiority trial. To be eligible, patients need to have histologically confirmed newly diagnosed glioblastoma. A total of 750 patients will be enrolled and randomized 1:1. Stratification factors include institution, age, Karnofsky performance status and extent of surgery. The primary objective of this study is to compare overall survival in patients receiving marizomib in addition to standard treatment (TMZ/RT→TMZ) with patients receiving standard treatment only. The testing strategy is defined to assess this objective in both the intent-to-treat population and the subgroup of patients with tumors harboring an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter. Secondary endpoints include progression-free survival, safety, neurocognitive function and quality of life. An accompanying translational research program has been set up. The study will be opened at 50 EORTC sites in Europe and done as an intergroup collaboration with the Canadian Cancer Trials Group (CCTG) with 25 sites in Canada and additional sites in the US. Patient enrolment is planned to start in June 2018 and an update on the enrolment status will be provided at the SNO conference. ClinicalTrials.gov Identifier: NCT03345095
Discussions before the Sections.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Valproic acid (Depakene). A new anticonvulsant agent
Authors: J. R. Lewis
Journal: JAMA (1978)

Valproic acid, a new anticonvulsant, is most effective in absence seizures (simple and complex), but it has produced improvement in tonicclonic seizures, mixed absence with tonic-clonic seizures, and myoclonic epilepsy. It is useful alone or as an adjunct to other anticonvulsants and may allow the dosage of the latter to be reduced. Some patients who are refractory to other anticonvulsants may respond to valproic acid. Adverse reactions occur in about 20% of patients. Gastrointestinal disturbances and drowsiness (usually noted when valproic acid is given with other anticonvulsants) are the most common reactions; hair loss is observed less frequently. Untoward effects are usually transient and do not require discontinuation of use of the drug. (<i>JAMA</i>240:2190-2192, 1978)
THE SOCIAL TRAINING OF THE PHYSICIAN.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiotensin-converting enzyme gene polymorphism predicts aldosterone escape in chronic heart failure patients Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, Lorenzo Franceschini, Giorgio Golia, Giulio Cabrini, Alberto Bonizzato, Maristella Graziani, Piero Zardini, Divisione Clinicizzata di Cardiologia, Verona, Italy
Journal: Journal of the American College of Cardiology (2001)
Frozen Sections
Authors: DWIGHT K. OXLEY
Journal: JAMA (1985)

<h3>To the Editor.—</h3> As a pathologist, I believe I understand some of the sentiments expressed by Dr Kindschi<sup>1</sup>regarding the use of frozen sections in the practice of surgery and surgical pathology. Kindschi, however, makes no mention of the fundamental medical issue—intraoperative consultations by pathologists. Pathologists who make themselves available for consultations during surgery perform a very valuable patient care function and also participate in making the decision as to whether a frozen section is indicated. I am told that there are hospitals where pathologists merely receive pieces of tissue in the laboratory, perform frozen sections, and communicate their findings via an intercom. Such a deplorable practice in which effective surgeon-to-pathologist communication is blocked obviously fosters the abuse of frozen sections. Kindschi mentions a study in which 42% of frozen sections were unnecessary. Interestingly, in our practice approximately 30% to 40% of intraoperative consultations do not involve the performance
"DINITROPHENOL POISONING"
Authors: Bertha L. Isaacs
Journal: JAMA (1934)

<h3>To the Editor:—</h3> I should like to make a correction in the article on "Dinitrophenol Poisoning" reported by Drs. Jackson and Duvall inThe Journal, June 2. Under the chemical analyses Dr. Jackson reported an icterus index of 20 on first examination. At the time the examination was made it was brought to Dr. Jackson's attention that the color obtained at that reading was almost entirely dissipated by the addition of 5 per cent hydrochloric acid. This is according to recommendation made by Dr. Tainter and his co-workers inThe Journalof Nov. 4, 1933. A second determination could not be made at this time because of lack of serum. The second report of 5.3 was obtained on later serum (also dark in color), which was decolorized with 5 per cent hydrochloric acid. I make this correction in order that the report may not be accepted by some as conclusive
Implications of Pharmacokinetic Modeling in Risk Assessment Analysis
Authors: Robert J. Lutz, Robert L. Dedrick
Journal: Environmental Health Perspectives (1987)

Physiologic pharmacokinetic models are a useful interface between exposure models and risk assessment models by providing a means to estimate tissue concentrations of reactive chemical species at the site of action. The models utilize numerous parameters that can be characterized as anatomical, such as body size or tissue volume; physiological, such as tissue blood perfusion rates, clearances, and metabolism; thermodynamic, such as partition coefficients; and transport, such as membrane permeabilities. The models provide a format to investigate how these parameters can influence the disposition of chemicals throughout the body, which is an important consideration in interpreting toxicity studies. Physiologic models can take into account nonlinear effects related to clearance, metabolism, or transport. They allow for extrapolation of tissue concentration from high dose to low dose experiments and from species to species and can account for temporal variations in dose.
In Reply:
Authors: Hanna J. Khoury, John F. DiPersio
Journal: Journal of Clinical Oncology (2005)

In their letter, Akhtar and Maghfor diligently highlight important pitfalls related to retrospective database analyses.Most, if not all, points raised in their comments were already addressed in the Discussion section of our article. 1Indeed, far from drawing a cause-effect relationship, our article simply describes associations between the pretransplant administration of rituximab and outcomes of autologous stemcell transplantation in a group of chemosensitive relapsed non-Hodgkin's lymphoma (primary induction failure and refractory relapses are not autografted at our center).This question is practically unanswerable in a prospective randomized trial, due to the increasing use of rituximab in non-Hodgkin's lymphoma patients.Figure 1 in the article summarizes trends in the administration of rituximab before referral to our center for autografting (including 2003 patients); however, only patients with at least 6 months of follow-up (transplantation before June 2003) were included in the analysis.Additionally, only commonly accepted prognostic indicators (age, time from diagnosis to relapse/transplant, 2 number of prior chemotherapy regimens) with the exception of the IPI score at relapse 3 (information not available in our database) were included in multivariate analyses.To our knowledge, neither pretransplantation therapy (induction 4 or salvage) nor conditioning 5 affects the outcomes of autografting for NHL.Finally, we agree with Akhtar and Maghfor that our article provides no explanation for the delay in platelets recovery in patients who received rituximab pretransplantation.As mentioned in the Results section, this observation is independent of age, time from diagnosis to transplantation, number of chemotherapy courses pretransplantation, number of CD34 ϩ cells infused, and timing of administration of rituximab (Ͻ 3 or Ͼ 3 months).Interestingly, no significant bleeding was observed among our 273 transplantation patients, regardless of prior administration of rituximab, confirming the commonly accepted notion that bleeding after state-ofthe-art autologous transplantation is a rather uncommon complication.